Author: Zhang, Shengyu; Li, Lei; Shen, Aizong; Chen, Yongwu; Qi, Zhigang
Title: Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia Cord-id: nqprluto Document date: 2020_4_26
ID: nqprluto
Snippet: Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that â“ 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been ap
Document: Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that ⓠ15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and “Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)†in China, so as to provide reference for the treatment of COVID-19.
Search related documents:
Co phrase search for related documents- acute kidney injury and additional dose: 1, 2
- acute kidney injury and liver damage: 1, 2, 3, 4, 5, 6
- acute kidney injury and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66
- acute kidney injury and liver injury patient: 1
- acute kidney injury and liver renal: 1, 2, 3
- acute kidney injury and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute kidney injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- acute kidney injury shock and liver damage: 1, 2, 3
- acute kidney injury shock and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute kidney injury shock and lung disease: 1, 2, 3
- acute kidney injury shock and lymphocyte count: 1, 2, 3, 4, 5, 6
- acute reactive protein and adaptive immunity: 1
- acute reactive protein and liver damage: 1
- acute reactive protein and lung disease: 1, 2, 3
- acute reactive protein and lymphocyte count: 1, 2
- acute shock follow respiratory distress syndrome and lung disease: 1
- adaptive immunity and liver damage: 1, 2, 3
- adaptive immunity and liver injury: 1
- adaptive immunity and liver renal: 1
Co phrase search for related documents, hyperlinks ordered by date